We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Investors Event Calendar
Environmental, Social and Governance (ESG)
ESG Updates: July 22, 2021 (PDF 1.8 MB) | Apr 28, 2021 (PDF 0.3 MB) | Jan 27, 2021 (PDF 0.5 MB) | Oct 28, 2020 (PDF 0.5 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessments Webinars
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Novartis ESG Investor Day 2021
Novartis shared progress on its most material ESG topics.
Third quarter results 2021
October 26, 2021
Basel, Switzerland
Watch the webcast
14:00 CEST | 13:00 BST | 08:00 EDT
Stocks
Media Releases
Pulse Updates
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
September 03, 2021
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
Novartis COVID-19 Information Center
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay Up-to-Date
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland